NCT06165965

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

A Randomized, Open-label, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of JLP-2008 and the Co-admin. of JT-001, and JT-002 for Healthy Subjects in Fasted State

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Jeil Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety and pharmacokinetic characteristics after the administration of JT-001, JT-002 and JLP-2008

Detailed description

A randomized, open-label, single oral dosing, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of JLP-2008 and the co-administration of JT-001, and JT-002 for healthy subjects in fasted state

Conditions

• Healthy Adult

Interventions

Type	Name	Description
DRUG	SGLT2 inhibitor	SGLT2 dual inhibitor

Timeline

• Start date: 2022-05-03
• Primary completion: 2022-06-13
• Completion: 2022-06-27
• First posted: 2023-12-12
• Last updated: 2023-12-12

Locations

1 site across 1 country: South Korea